Voloridge Investment Management
CATX icon

Voloridge Investment Management’s Perspective Therapeutics CATX Stock Holding History

Voloridge Investment Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,963
Closed -$159K – 1177
2024
Q2 		$159K Buy
+15,963
New +$231K ﹤0.01% 1178

Other funds holding CATX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NWMG
Nicholson Wealth Management Group Charlestown, South Carolina $172M AUM 10.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Voloridge Investment Management's CATX Position: Q3 2024 in Review

Voloridge Investment Management sold out of Perspective Therapeutics (CATX) in Q3 2024, closing a stake of 15,963 shares — an estimated $159K sold.

Voloridge Investment Management first reported a position in CATX in Q2 2024 and held it in 1 quarter. The position peaked at $159K in Q2 2024. 127 funds tracked by Wall St. Rank hold CATX as of Q3 2024.

  • Voloridge Investment Management reported no remaining Perspective Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Voloridge Investment Management sold 15,963 Perspective Therapeutics shares in Q3 2024, an estimated $159K.
  • Voloridge Investment Management first reported a position in Perspective Therapeutics in Q2 2024 and held it in 1 quarter.
  • Voloridge Investment Management's Perspective Therapeutics position peaked at $159K in Q2 2024.
  • 127 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q3 2024.

Based on Voloridge Investment Management's 13F filing for Q3 2024, filed 14 Nov 2024.